s:**
- Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engineered vs native antibodies
- Test whether pH-modified variants retain microglia

V2, Crosslink

🧫

s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engineered vs native antibodies - Test whether pH-modified variants retain microglia

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-debate-0303c1c48688

🧫 Experiment Protocol Falsificationproposed

SUMMARY

# s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engineered vs native antibodies - Test whether pH-modified variants retain microglia ## Background and Rationale This falsification experiment investigates the role of the neonatal Fc receptor (FcRn) in antibody-mediated therapeutics for neuroinflammation by comparing brain penetration and therapeutic efficacy of engineered versus native antibodies in FcRn-competent and FcRn-deficient mice. The study addresses critical questions

METHODOLOGY NOTES

**Phase 1: Animal Preparation and Genotyping (Days 1-7)** • Obtain 48 C57BL/6J mice (24 FcRn+/+ and 24 FcRn-/-) aged 8-12 weeks • Confirm genotypes via PCR analysis of tail biopsies • Acclimate animals for 7 days in controlled environment (12h light/dark, 22±2°C) • Fast animals 12h before antibody administration **Phase 2: Antibody Preparation and Characterization (Days 5-8)** • Prepare four antibody variants: native IgG1, pH-modified IgG1 (His-substituted Fc), native anti-CD11b, pH-modified anti-CD11b • Confirm pH-dependent FcRn binding via surface plasmon resonance (pH 6.0 vs 7.4) • Label antibodies with fluorescent dyes (Alexa Fluor 647) for real-time tracking • Validate antibody integrity and binding capacity via flow cytometry **Phase 3: Real-Time Transcytosis Imaging Setup (Days 8-9)** • Install cranial windows in subset of mice (n=6 per genotype) under isoflurane anesthesia • Allow 48h recovery period with analgesics (buprenorphine 0.1mg/kg) • Calibrate two-photon microscopy s

▸Metadatasource: {'type': 'manual', 'source_name': 'debat

source	{'type': 'manual', 'source_name': 'debate_extraction', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.910213Z'}
summary	# s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engineered vs native antibodies - Test whether pH-modified variants retain microglia ## Background and Rationale This falsification e
entities	{'genes': ['ABCB1/C1QA/CAV1'], 'diseases': ['Neuroinflammation']}
model_system	mouse
_schema_version	1
experiment_type	falsification
primary_outcome	Brain antibody concentration measured by ELISA and autoradiography 24-72 hours post-injection, comparing FcRn+/+ versus FcRn-/- mice treated with native versus engineered pH-sensitive antibody variant
methodology_notes	Phase 1: Animal Preparation and Genotyping (Days 1-7) • Obtain 48 C57BL/6J mice (24 FcRn+/+ and 24 FcRn-/-) aged 8-12 weeks • Confirm genotypes via PCR analysis of tail biopsies • Acclimate animal
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.910219', 'needs_review': True, 'extraction_notes': 'Backfilled from debate_extraction source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

232

Outgoing

127

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engineered vs native antibodies - Test whether pH-modified variants retain microglia

derives from (15)

supports (110)

💬 Discussion